10 recruiting, 8 active not recruiting, 7 terminated, 6 completed. 22 Phase 1, 14 Phase 2, 5 Phase 3, 1 Early Phase 1.
Follow adagrasib: new trials by email Literature Review of adagrasib trials Research Report on adagrasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer Adagrasib, Biospecimen Collection, Computed Tomography - Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 29 | 2026-10-15 | 2026-09-02 |
| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent Adagrasib - Healthy Participants | Phase 1 | Completed | Mirati Therapeutics Inc. | 10 | 2026-08-05 | 2026-09-28 |
| Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial Adagrasib, Iza-bren - Non-small Cell Lung Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-05-15 | 2026-08-11 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies Adagrasib, Pembrolizumab, Cetuximab - Solid Tumors | Phase 2 | Recruiting | Mirati Therapeutics Inc. | 170 | 2026-05-06 | 2026-10-27 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) Adagrasib, Pembrolizumab, Carboplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | Mirati Therapeutics Inc. | 630 | 2025-04-24 | 2026-10-27 |
| A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors BMS-986488, Adagrasib, Cetuximab - Advanced Malignant Tumors | Phase 1 | Recruiting | Bristol-Myers Squibb | 437 | 2025-03-25 | 2026-07-29 |
| Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets Adagrasib - Healthy Volunteers | Phase 1 | Completed | Mirati Therapeutics Inc. | 160 | 2025-02-04 | 2025-07-16 |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Divarasib, Sotorasib, Adagrasib - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 338 | 2024-09-23 | 2026-09-16 |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations Cetuximab, Cemiplimab, Adagrasib - Metastatic Colorectal Cancer, KRAS G12C Mutations | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 31 | 2024-08-28 | 2026-06-26 |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases Adagrasib, Stereotactic Radiosurgery - Non Small Cell Lung Cancer, NSCLC | Phase 2 | Recruiting | Ryan Gentzler, MD | 30 | 2024-08-06 | 2026-04-08 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Adagrasib - Advanced Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 200 | 2024-02-01 | 2026-08-14 |
| Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers Adagrasib, Olaparib - Advanced Solid Tumor, Non-small Cell Lung Cancers | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2024-01-30 | 2026-04-09 |
| A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation INCB099280, adagrasib - Advanced Solid Tumors | Phase 1 | Terminated | Incyte Corporation | 6 | 2023-12-28 | 2026-09-08 |
| Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer MRTX849, Irinotecan, Cetuximab - Colon Cancer, Colorectal Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2023-12-06 | 2026-08-14 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors BMS-986466, Adagrasib, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2023-11-09 | 2025-07-22 |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Darlifarnib, Cabozantinib, Adagrasib - Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Kura Oncology, Inc. | 300 | 2023-10-18 | 2026-10-14 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC | Phase 1 | Terminated | Mirati Therapeutics Inc. | 6 | 2023-08-07 | 2025-04-25 |
| A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib Adagrasib, Eltrombopag + adagrasib - Healthy Adults | Phase 1 | Completed | Mirati Therapeutics Inc. | 16 | 2023-06-29 | 2024-03-13 |
Showing 20 of 37. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (17) · Colorectal Neoplasms (11) · Neoplasm Metastasis (11) · Lung Neoplasms (7) · Neoplasms (7) · Colonic Neoplasms (6) · Pancreatic Neoplasms (4) · Carcinoma, Renal Cell (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Kidney Neoplasms (1) · Rectal Neoplasms (1)
Mirati Therapeutics Inc. (15) · M.D. Anderson Cancer Center (7) · Bristol-Myers Squibb (3) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · ETOP IBCSG Partners Foundation (1) · Hoffmann-La Roche (1) · Incyte Corporation (1) · Kura Oncology, Inc. (1) · Roswell Park Cancer Institute (1) · Ryan Gentzler, MD (1) · Sanofi (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Verastem, Inc. (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (35) · Spain (11) · France (10) · Italy (10) · Australia (9) · South Korea (8) · United Kingdom (8) · Belgium (7) · Germany (7) · Greece (7) · Netherlands (7) · Poland (7) · Brazil (6) · Canada (6) · China (6)
Christine Parseghian, MD (1) · Dan Zhao, MD (1) · David S. Hong, MD (1) · Grace K Dy (1) · Jarushka Naidoo (1) · Kristen Marrone (1) · MD Verastem (1) · Marcelo V Negrao, MD (1) · Marcelo V. Negrao, MD (1) · Priscilla Brastianos, MD (1)
PMID 38579193, PMID 32479604, PMID 34161704, PMID 35167329, PMID 35404402, PMID 35658005, PMID 36546659, PMID 37099736, PMID 37327468, PMID 39752885, PMID 40783289, PMID 42745627
2023 (4), P30CA033572 (1), U10CA180821 (1)